AMRN earnings analysis
What we found in AMRN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Amarin Corporation's Q1 2026 report revealed a strong performance with revenues of $45.1 million, surpassing estimates, and a notable improvement in diluted EPS at -$0.03, significantly beating the expected -$0.41. Management remains optimistic about achieving positive cash flow for the full year 2026, aided by recent cost optimization initiatives, despite facing ongoing competition and restructuring costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeds Expectations
- Q1 2026 revenues were $45.1 million, beating the consensus of $43.4 million.
- Significant EPS Improvement
- Diluted EPS was -$0.03, much better than the expected -$0.41.
- Cost Optimization Progress
- Management highlighted successful initial steps in cost optimization that support revenue growth.
- Confidence in Positive Cash Flow
- Amarin reaffirms expectations for positive cash flow throughout 2026.
- Inventory Management
- Inventory stood at $183.6 million, ensuring supply chain stability.
- R&D Emphasis on VASCEPA
- Continued investment in research supports future growth in cardiovascular therapeutics.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Restructuring Costs
- Ongoing restructuring could lead to additional expenses impacting short-term margins.
- Generic Competition
- Increased competition from approved generics for VASCEPA may erode market share.
- European Revenue Decline
- Continued softness in European sales could negatively affect overall performance.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.03
What they said about what is next.
Management anticipates maintaining positive cash flow throughout 2026.
The filing reads better than the one before it.
What came before.
- 10-K · March 2, 2026
- Amarin remains a single-product commercial pharmaceutical company centered on VASCEPA/VAZKEPA; Q4 2025 revenue was $49,219,000 with GAAP EPS of $0.01, while management is pursuing cost reduction and partnership-led…
- 10-Q · May 7, 2025
- Amarin reported Q1 revenue of $42.0M, down $14.5M (-25.7%) versus Q1 2024, with gross margin improving to 59.8% but operating loss widening to $16.8M (-39.9% of revenue) and net loss of $15.7M (diluted loss per share…
- 10-Q · October 30, 2024
- Amarin reported Q3 net revenue of $42.298M, a sharp decline from $66.056M in the year‑ago quarter, driving a lower gross margin (38.5%) and a wider quarterly net loss of $25.134M (EPS -$0.06). Liquidity remains strong…
- 10-Q · July 31, 2024
- Amarin reported Q2 total revenue of $67.49M (down from $80.17M in Q2 2023) and GAAP net income of $1.522M (basic/diluted EPS $0.00) versus a $17.56M loss in Q2 2023. Gross margin expanded to 63.4% (from 53.2% in Q2…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AMRN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever